Tag: ADAURA

Yale Cancer Center Expert Reports Significant Improvement in Survival for Lung Cancer Patients in the ADAURA Phase III Trial, involving AstraZeneca’s Targeted Therapy Drug, Tagrisso

sarah JonasExpert Pitch

New data released from the ADAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a significant improvement in overall survival, compared to placebo in the adjuvant treatment of patients with early stage EGFR-mutated lung cancer. Roy S. Herbst, MD, PhD, deputy…